Wenger Vieli advised Xeltis, a med-tech company developing regenerative cardiovascular implants, on all Swiss legal and tax aspects in connection with its recent financing round totaling nearly EUR 50 million. The financing consists of up to EUR 37.5 million from the European Investment Bank (EIB), supported under the InvestEU programme, and EUR 10 million from existing shareholders including EQT Life Sciences and Invest-NL.
The funds will help bring aXess - a new type of implant that provides reliable blood access for patients undergoing kidney dialysis - to the market. They will also support expanding production, hiring additional staff, and further developing Xeltis’ regenerative implant technologies.
The team was led by Beat Speck (Partner, Corporate/M&A) and included Jonas Bühlmann (Counsel, Tax), Micha Schilling (Counsel, Financing), Fabienne Nufer (Associate, Corporate/M&A) and Dario Schönbächler (Associate, Corporate/M&A).